Hiroki Morimura
Osaka, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
Atezolizumab plus Bevacizumab versus Lenvatinib as First-Line Treatment for Unresectable Hepatocellular Carcinoma Stratified by the CRAFITY Score: An International Multicenter Study.
Journal: Liver cancer
Published: February 06, 2026
Lenvatinib Versus Atezolizumab Plus Bevacizumab as First-Line Treatment for Advanced Hepatocellular Carcinoma With a CRAFITY Score of 2: A Multi-Center Retrospective Study.
Journal: Hepatology research : the official journal of the Japan Society of Hepatology
Published: June 20, 2025
Publisher Correction: CRAFITY score as a predictive marker for refractoriness to atezolizumab plus bevacizumab therapy in hepatocellular carcinoma: a multicenter retrospective study.
Journal: Journal of gastroenterology
Published: October 21, 2024
CRAFITY score as a predictive marker for refractoriness to atezolizumab plus bevacizumab therapy in hepatocellular carcinoma: a multicenter retrospective study.
Journal: Journal of gastroenterology
Published: June 05, 2024
Primary Retroperitoneal Mucinous Cystadenocarcinoma during Long-term Administration of Infliximab for the Treatment of Crohn's Disease.
Journal: Internal medicine (Tokyo, Japan)
Published: May 10, 2023
Primary Hepatic Neuroendocrine Carcinoma with Thrombocytopenia Due to Diffuse Bone Marrow and Splenic Infiltration: An Autopsy Case.
Journal: Internal medicine (Tokyo, Japan)
Published: April 11, 2022
Longly-attached cap can contribute to en bloc underwater endoscopic mucosal resection of 20-30 mm colorectal intramucosal lesions.
Journal: Endoscopy international open
Published: March 23, 2022
Reactivation from occult HBV carrier status is characterized by low genetic heterogeneity with the wild-type or G1896A variant prevalence.
Journal: Journal of hepatology
Published: December 10, 2013
Showing 1-9 of 9
Last Updated: 09/26/2026